Enhancing treatment for mucosal melanoma using a modified virus
Official title: Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMV
Funded at Northwestern University at Chicago · NIH-11073845 · Data updated 2026-11-12
This study is exploring a new way to treat mucosal melanoma using a modified virus that could help your immune system fight the cancer better, with the goal of finding a safer and more effective treatment for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $667,553 |
| NIH project number | 1R01CA298377-01 |
| Project ID | NIH-11073845 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with mucosal melanoma or those who may benefit from innovative cancer immunotherapies.
✕Less likely to help
Patients with non-melanoma skin cancers or those who do not have mucosal melanoma may not receive benefits from this research.
What this research studies
This research investigates a novel approach to treating mucosal melanoma by utilizing a modified version of the lymphocytic choriomeningitis virus (r3LCMV). The study aims to harness the virus's ability to trigger strong immune responses against tumors, potentially improving the effectiveness of cancer therapies. By testing this approach in both animal models and human applications, the researchers hope to develop a safer and more effective treatment option for patients with this aggressive form of melanoma. The project will focus on the virus's direct effects on tumor cells and its ability to stimulate the immune system.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with mucosal melanoma.
How similar studies have gone: Previous research has shown promising results with viral-based therapies for cancer, indicating potential success for this novel approach.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Pollack, Seth M — Northwestern University at Chicago
- Study coordinator: Pollack, Seth M
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.